Comparing Skyrizi vs Stelara ; Skyrizi has an average rating of 8.0 out of 10 from a total of 47 ratings on Drugs.com. 75% of reviewers reported a positive
View efficacy data showing the superior rates of SKYRIZI of PASI 90 at 2.5 years from clinical trial of SKYRIZI (risankizumab-rzaa) vs STELARA (ustekinumab). See SKYRIZI benefits, risks, and important safety information.
More patients with Crohn's disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara.
After an initial loading dose, Tremfya is administered every 8 weeks, Ilumya, Stelara, and Skyrizi are administered every 12 weeks; All are effective; Skyrizi has a faster onset of action; A comparative trial that compared Skyrizi to Stelara found Skyrizi to be more effective.
View efficacy data showing the superior rates of SKYRIZI of PASI 90 at 2.5 years from clinical trial of SKYRIZI (risankizumab-rzaa) vs STELARA (ustekinumab).
More patients with Crohn's disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara.
Yeah then personally I'd go with Rinvoq. Skyrizi recently did a head to head trial against Stelara. Double the amount of people responded to Skyrizi compared to Stelara so it does look like there are likely people who fail Stelara, but would respond to Skyrizi.
Stelara vs Skyrizi COPENHAGEN, DenmarkRisankizumab(Skyrizi, AbbVie) shows noninferiority for clinical remission at week 24, and superiority
View efficacy data showing the superior rates of SKYRIZI of PASI 90 at 2.5 years from clinical trial of SKYRIZI (risankizumab-rzaa) vs STELARA (ustekinumab). See SKYRIZI benefits, risks, and important safety information.
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are